Form 8-K - Current report:
SEC Accession No. 0000950142-22-001784
Filing Date
2022-05-31
Accepted
2022-05-31 16:37:44
Documents
15
Period of Report
2022-05-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh220256851_8k.htm   iXBRL 8-K 28248
2 EXHIBIT 99.1 eh220256851_ex9901.htm EX-99.1 12993
3 GRAPHIC company_logo.jpg GRAPHIC 10406
  Complete submission text file 0000950142-22-001784.txt   272885

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nrxp-20220525.xsd EX-101.SCH 3690
5 XBRL DEFINITION FILE nrxp-20220525_def.xml EX-101.DEF 26608
6 XBRL LABEL FILE nrxp-20220525_lab.xml EX-101.LAB 36687
7 XBRL PRESENTATION FILE nrxp-20220525_pre.xml EX-101.PRE 25232
9 EXTRACTED XBRL INSTANCE DOCUMENT eh220256851_8k_htm.xml XML 5562
Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 22983984
SIC: 2834 Pharmaceutical Preparations